Home > News > APP Announces FDA Acceptance of New Drug
May 10th, 2004
APP Announces FDA Acceptance of New Drug
American Pharmaceutical Partners, Inc. and American BioScience, Inc.today announced that the New Drug Application for ABRAXANETM has been accepted for filing with standard review by the U.S. Food and Drug Administration, indicating the FDA has determined that the application is sufficiently complete to permit a substantive review. The final portion of the NDA was submitted on March 8, 2004 under FDA's Fast Track designation, as a treatment for metastatic breast cancer.
Laser light at useful wavelengths from semiconductor nanowires: Nanowire lasers could work with silicon chips, optical fibers, even living cells December 5th, 2013
DNA helicity and elasticity explained on the nanoscale: Korean researchers propose simple model to explain DNA helicity and elasticity on a nanometer scale December 5th, 2013
Curing Cancer with Magnetic Nanoparticles December 4th, 2013
High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke December 4th, 2013